Archive: Company News
Company News: Curetis Provides Business Update for the First Nine Months of 2019
– Signed IVD partnership for Ares Genetics
– Progressed implementation of the Curetis – OpGen business combination with S4 filing
– More than tripled total contract order volume received year-over-year to EUR 3.4 million in 9M-2019
– Revenue growth of approximately 16%
– Near-term FDA decision on clearance of Unyvero LRT for BAL specimen expected
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today provided a business update for the first nine months ended September 30, 2019, including key financial results.
Company News: Evonik and BellaSeno partner to enable the launch of an innovative 3D printed breast implant technology
— 3D printed breast scaffolds to be made of RESOMER®
— Degradation of RESOMER® to match the growth of the patient’s own tissue for natural breasts
— Technology designed to improve quality of life for patients after breast reconstruction and augmentation
— Human clinical trials to commence later this year
Evonik, a global leader in biomaterials for implantable medical devices, and BellaSeno GmbH, a developer of 3D printed absorbable scaffolds, today announced the signing of a long-term agreement for the use of a RESOMER® bioresorbable polymer for an innovative breast implant technology.
Company News: Curetis To Attend Key Conferences in the Fourth Quarter of 2019
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that the Curetis Group Companies will be attending several key conferences in the fourth quarter of 2019.
Company News: Curetis Group Company Ares Genetics Launches AI-powered Molecular Antibiotic Susceptibility Test
— Blinded evaluation study with leading global IVD player demonstrated diagnostic performance in line with FDA requirements for antibiotic susceptibility testing (AST)
— Already received orders for more than1,000 molecular AST tests offered under the brand name ARESupa – Universal Pathogenome Assay
— Total contractual order volume received in 2019 for next-generation sequencing tests as well as advanced bioinformatics, AI services and certain rights amounts to over EUR 2 million
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Genetics has launched an early access program for its novel, artificial intelligence (AI) powered, next-generation sequencing (NGS) based molecular antibiotic susceptibility test (AST).